Literature DB >> 21874257

Re-expression of estrogen receptor β inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells.

Jing Zhu1, Keqin Hua, Hong Sun, Yinhua Yu, Hongyan Jin, Youji Feng.   

Abstract

Ovarian clear cell adenocarcinoma (OCCA) is an aggressive ovarian malignancy with a poor prognosis. The role of estrogen receptor β (ERβ) in the development of OCCA remains to be clarified. To investigate the action of ERβ in the proliferation and invasion of OCCA cells, the ES-2 cell line was stably transfected with full-length human ERβ cDNA, and clones were screened and identified using RT-PCR and western blot assay. ERβ stable transfectants, referred to as ESβ1 and ESβ2 cells, were compared with mock transfectant ESVE and parental ES-2 cells with respect to their growth, motility and ability to activate target genes. ESβ1 and ESβ2 cells expressed ERβ mRNA and protein, whereas ES-2 and ESVE cells were ERβ negative. ERβ transfectants exhibited distinct characteristics from ES-2 and ESVE cells including proliferative properties and the ability to express cyclin D1 in the presence of 17β-estradiol (E2). ERβ inhibited ES-2 cell proliferation, which was determined using the MTT assay, BrdU labeling method and by the down-regulation of cyclin D1 gene expression. Moreover, exogenous ERβ expression resulted in a significant inhibition of ES-2 cell motility in an in vitro invasion assay. ERβ reduced the expression of MMP2 mRNA and the activity of MMP2 enzymatic activity in a ligand-dependent manner. In summary, ERβ may inhibit the proliferation and invasion of ES-2 cells and may be an important regulator in OCCA carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874257     DOI: 10.3892/or.2011.1430

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

Review 2.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

3.  Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells.

Authors:  Susanne Schüler-Toprak; Christoph Moehle; Maciej Skrzypczak; Olaf Ortmann; Oliver Treeck
Journal:  BMC Cancer       Date:  2017-05-08       Impact factor: 4.430

4.  Estrogen Receptor Beta Inhibits The Proliferation, Migration, And Angiogenesis Of Gastric Cancer Cells Through Inhibiting Nuclear Factor-Kappa B Signaling.

Authors:  Yiping Zhang; Yahua Wu; Xufeng Zhou; Benyi Yi; Lili Wang
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.147

Review 5.  ERβ Regulation of Gonadotropin Responses during Folliculogenesis.

Authors:  Eun B Lee; V Praveen Chakravarthi; Michael W Wolfe; M A Karim Rumi
Journal:  Int J Mol Sci       Date:  2021-09-26       Impact factor: 5.923

6.  Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.

Authors:  Karen K L Chan; Michelle K Y Siu; Yu-Xin Jiang; Jing-Jing Wang; Yan Wang; Thomas H Y Leung; Stephanie S Liu; Annie N Y Cheung; Hextan Y S Ngan
Journal:  BMC Cancer       Date:  2017-08-31       Impact factor: 4.430

7.  Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth.

Authors:  Laura Verardi; Jessica Fiori; Vincenza Andrisano; Alessandra Locatelli; Rita Morigi; Marina Naldi; Carlo Bertucci; Elena Strocchi; Carla Boga; Gabriele Micheletti; Natalia Calonghi
Journal:  Molecules       Date:  2020-09-27       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.